8-K: Oramed Completes Oratech Sale, Invests in Lifeward

Oramed Pharmaceuticals Inc. announced the completion of its sale of Oratech Pharma to Lifeward Ltd. and a concurrent $9 million investment in Lifeward.

Summary

• Oramed Pharmaceuticals Inc. completed the sale of its wholly-owned subsidiary, Oratech Pharma, Inc., to Lifeward Ltd. on March 25, 2026.
• In consideration for Oratech, Oramed received 1,250,363 Lifeward Ordinary Shares, 1,006,113 Pre-Funded Warrants (exercise price $0.0001/share), and Share Purchase Warrants for up to 1,296,296 Lifeward Ordinary Shares (initial exercise price $5.40/share).
• Oramed will also receive ongoing revenue-based payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties for up to 10 years, or until a maximum amount is reached, or Lifeward's market capitalization exceeds $200 million.
• Concurrently, Oramed invested $9,000,000 in Lifeward by purchasing senior secured convertible notes in a private placement.
• These notes are convertible into Lifeward Ordinary Shares at an initial conversion price of $5.40 per share.
• Oramed also received Purchase Agreement Warrants to acquire up to 1,666,666 Lifeward Ordinary Shares at an initial exercise price of $5.40 per share as part of the notes purchase.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive strategic move, allowing Oramed to divest a subsidiary while maintaining significant financial exposure and potential upside through equity, warrants, and revenue sharing, alongside a strategic investment.

Positives

• Oramed monetized its Oratech subsidiary, receiving a combination of equity, warrants, and future revenue sharing from Lifeward.
• The revenue sharing agreement provides a potential long-term income stream tied to the success of Lifeward's ReWalk Personal Exoskeleton products.
• Oramed's $9 million investment in Lifeward through convertible notes and warrants provides exposure to Lifeward's potential growth while offering a senior secured position.
• The transaction allows Oramed to streamline its focus while retaining a significant stake and potential upside in the divested asset's future.

Negatives

• The sale of Oratech means Oramed no longer directly controls the subsidiary's operations or future development.
• The revenue sharing payments are capped by a maximum amount and can terminate if Lifeward's market capitalization reaches $200 million, potentially limiting long-term upside from the divested asset.
• Oramed has committed $9,000,000 in capital to Lifeward, which could be deployed elsewhere or retained as cash.

Risks

• The value of the Lifeward Ordinary Shares and warrants received by Oramed is subject to the future performance and market valuation of Lifeward Ltd.
• Revenue Sharing Payments are contingent on the Net Revenue of Lifeward's ReWalk Personal Exoskeleton products, which may fluctuate or not meet expectations.
• The conversion and exercise prices of the notes and warrants are subject to adjustments, which could impact Oramed's ultimate ownership percentage or return.
• Oramed's investment in Lifeward's senior secured convertible notes carries inherent risks associated with debt and equity investments in another company.

Future Outlook

The filing details the completion of a strategic transaction involving the divestiture of a subsidiary and a significant investment in the acquiring company. It implies Oramed's future financial performance will be influenced by its equity stake, warrants, and revenue sharing agreement with Lifeward, as well as the performance of its $9 million convertible note investment.

Management Comments

• Nadav Kidron, President and CEO of Oramed Pharmaceuticals Inc., signed the report.

Industry Context

StockSavvy.ai notes that this transaction represents a strategic shift for Oramed, potentially allowing it to focus on its core pharmaceutical pipeline while retaining exposure to the medical device sector through its investment in Lifeward, a company known for its ReWalk Personal Exoskeleton products. This could be seen as a move to optimize asset allocation and leverage specialized expertise.

Comparison to Industry Standards

• The structure of the deal, involving a mix of equity, warrants, and revenue sharing, is common in biotech and medical device divestitures, allowing the seller to participate in future upside.
• The $9 million convertible note investment by Oramed into Lifeward is a substantial commitment, indicating confidence in Lifeward's future prospects and potentially providing Oramed with a strategic influence or partnership opportunity.
• The revenue sharing component, tied to specific product lines like the ReWalk Personal Exoskeleton, is a standard mechanism for retaining a financial interest in divested assets, similar to royalty agreements seen in pharmaceutical licensing deals.

Stakeholder Impact

• Shareholders: Oramed shareholders now have indirect exposure to Oratech's future through Lifeward equity and revenue sharing, and direct exposure to Lifeward through the convertible notes and warrants. The strategic focus of Oramed may become clearer.
• Employees (Oratech): Employees of Oratech are now part of Lifeward Ltd.
• Customers (ReWalk Exoskeleton): The transaction may impact the strategic direction or resources allocated to ReWalk products under Lifeward's full ownership.

Next Steps

• Oramed will monitor the performance of its Lifeward Ordinary Shares, Pre-Funded Warrants, Share Purchase Warrants, and Purchase Agreement Warrants.
• Oramed will receive Revenue Sharing Payments from Lifeward based on the Net Revenue of ReWalk Personal Exoskeleton products.
• Oramed will manage its $9,000,000 investment in Lifeward's senior secured convertible notes.

Key Dates

Recommendation

The completion of the Oratech sale and the concurrent investment in Lifeward represent a significant strategic restructuring for Oramed. While the divestiture allows for potential focus on core assets and the investment provides exposure to Lifeward's growth, the immediate impact on Oramed's valuation is complex, involving a mix of cash, equity, and future revenue streams. A "hold" recommendation is appropriate as investors assess the long-term value creation from this new strategic direction and the performance of Lifeward.

Keywords

Oramed Pharmaceuticals, Lifeward Ltd., Oratech Pharma, SEC Filing, 8-K, Acquisition, Disposition, Share Purchase Agreement, Convertible Notes, Warrants, Revenue Sharing, ReWalk Exoskeleton, Biotechnology, Pharmaceuticals, Medical Devices, Investment